PMID- 17473921
OWN - NLM
STAT- MEDLINE
DCOM- 20071025
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 56
IP  - 11
DP  - 2007 Nov
TI  - TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate 
      cancer.
PG  - 1785-93
AB  - Dendritic cells (DCs) are highly potent initiators of the immune response, but DC 
      effector functions are often inhibited by immunosuppressants such as transforming 
      growth factor beta (TGF-beta). The present study was conducted to develop a 
      treatment strategy for prostate cancer using a TGF-beta-insensitive DC vaccine. 
      Tumor lysate-pulsed DCs were rendered TGF-beta insensitive by dominant-negative 
      TGF-beta type II receptor (TbetaRIIDN), leading to the blockade of TGF-beta 
      signals to members of the Smad family, which are the principal cytoplasmic 
      intermediates involved in the transduction of signals from TGF-beta receptors to 
      the nucleus. Expression of TbetaRIIDN did not affect the phenotype of transduced 
      DCs. Phosphorylated Smad-2 was undetectable and expression of surface 
      co-stimulatory molecules (CD80/CD86) were upregulated in TbetaRIIDN DCs after 
      antigen and TGF-beta1 stimulation. Vaccination of C57BL/6 tumor-bearing mice with 
      the TbetaRIIDN DC vaccine induced potent tumor-specific cytotoxic T lymphocyte 
      responses against TRAMP-C2 tumors, increased serum IFN-gamma and IL-12 level, 
      inhibited tumor growth and increased mouse survival. Furthermore, complete tumor 
      regression occurred in two vaccinated mice. These results demonstrate that 
      blocking TGF-beta signals in DC enhances the efficacy of DC-based vaccines.
FAU - Wang, Fu-Li
AU  - Wang FL
AD  - Department of Urology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, Shaanxi, China.
FAU - Qin, Wei-Jun
AU  - Qin WJ
FAU - Wen, Wei-Hong
AU  - Wen WH
FAU - Tian, Feng
AU  - Tian F
FAU - Song, Bin
AU  - Song B
FAU - Zhang, Qiang
AU  - Zhang Q
FAU - Lee, Chung
AU  - Lee C
FAU - Zhong, Wei-de
AU  - Zhong WD
FAU - Guo, Ying-Lu
AU  - Guo YL
FAU - Wang, He
AU  - Wang H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070501
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Receptors, Transforming Growth Factor beta)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type II)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - *Cancer Vaccines/therapeutic use
MH  - Cell Line, Tumor
MH  - Dendritic Cells/immunology/*transplantation
MH  - Immunotherapy
MH  - Lymphocyte Activation/drug effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Prostatic Neoplasms/*drug therapy
MH  - *Protein Serine-Threonine Kinases/genetics/metabolism
MH  - Receptor, Transforming Growth Factor-beta Type II
MH  - *Receptors, Transforming Growth Factor beta/genetics/metabolism
MH  - Signal Transduction
MH  - T-Lymphocytes/drug effects/immunology
PMC - PMC11030160
EDAT- 2007/05/03 09:00
MHDA- 2007/10/27 09:00
PMCR- 2007/05/01
CRDT- 2007/05/03 09:00
PHST- 2006/11/19 00:00 [received]
PHST- 2007/03/23 00:00 [accepted]
PHST- 2007/05/03 09:00 [pubmed]
PHST- 2007/10/27 09:00 [medline]
PHST- 2007/05/03 09:00 [entrez]
PHST- 2007/05/01 00:00 [pmc-release]
AID - 322 [pii]
AID - 10.1007/s00262-007-0322-3 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2007 Nov;56(11):1785-93. doi: 
      10.1007/s00262-007-0322-3. Epub 2007 May 1.